^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

    Excerpt:
    Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation].
    Trial ID:
    RELAY
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age = 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

    Published date:
    11/06/2019
    Excerpt:
    ...131 previously untreated young (≤65 years) pts with MCL….Pts received IR induction (part-A),...Among the 10 pts with TP53 mutations, 70% had a CR on part A alone.
    DOI:
    https://doi.org/10.1182/blood-2019-126044
    Trial ID:
    NCI-2015-00960